Company: BSX
Filing Date: 2025-02-24
Form Type: 424B2
Source: 0001104659-25-016521
Chunk: 80

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-24
Form: 424B2
Chunk 80
---
 annual meeting of stockholders. Mr. Dockendorff’s decision not to stand for re-election at the next annual meeting of stockholders is not the result of any disagreement with Boston Scientific Corporation. None of the members of the Board of Directors have any potential conflicts of interest between the duties to Boston Scientific Corporation and their private interests or other duties. The business address for each of the above directors is Boston Scientific Corporation’s registered office at 2711 Centerville Road, Suite 400, Wilmington, Delaware 19808, USA. Board of Directors of AMS Europe

| Name of Director                  | ​ | ​ | Function          | ​ |
| Emily Woodworth                   | ​ | ​ | Managing Director | ​ |
| Carla Madrid Magalhães Nascimbeni | ​ | ​ | Managing Director | ​ |

None of the members of the Board of Directors of AMS Europe have any potential conflicts of interest between the duties to AMS Europe and their private interests or other duties. Directors of AMS Europe are employees of Boston Scientific Corporation and serve, and may continue to serve in the future, on the Board of Directors of other wholly-owned subsidiaries of Boston Scientific Corporation. The business address for each of the above directors is its registered office is located at Vestastraat 6, 6468 EX Kerkrade, The Netherlands. Corporate Authority AMS Europe has obtained all necessary consents, approvals and authorizations in connection with the issuance and performance of the notes.

S-43

TABLE OF CONTENTS

#### Persons Responsible
AMS Europe and Boston Scientific accept responsibility for the information contained in this prospectus supplement and the accompanying prospectus and, having taken all reasonable care to ensure that such is the case, the information contained in this prospectus supplement and the accompanying prospectus is, to the best of their knowledge, in accordance with the facts and contains no omission likely to affect its import.

#### Absence of Litigation
Except for the matters set out in Note I — Commitments and Contingencies in our 2024 Form 10-K for the fiscal year ended December 31, 2024, we are not involved (and have not been involved in the twelve months preceding the date of this prospectus supplement) in any governmental, legal or arbitration proceedings (including any such proceedings that are pending or threatened of which we are aware) that may have or have had in the recent past, significant effects on our financial position or profitability.

#### Absence of Significant Changes
There has been no material adverse change in our prospects and no